UBS Initiates Esperion Therapeutics With Buy
April 01, 2015 at 09:16 AM EDT
Analysts at UBS initiated coverage on Esperion Therapeutics, Inc. (NASDAQ: ESPR) with a Buy rating. The target price for Esperion ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.